CSN5i-3

05/23/2019 - "Overall, our study suggested that the Jab1 inhibitor CSN5i-3 might be a promising agent for the treatment of breast cancer in humans and should be studied further."
05/23/2019 - "We also found that CSN5i-3 significantly induced apoptosis and G1 phase cell cycle arrest in breast cancer cells. "
05/23/2019 - "An MTS assay revealed that CSN5i-3 suppressed cell proliferation in the breast cancer cell lines BT474 and SKBR3. "
05/23/2019 - "Therefore, we evaluated the anticancer effect of the novel Jab1 inhibitor CSN5i-3 in breast cancer cells. "
05/23/2019 - "The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells."

01/01/2020 - "Finally, we demonstrate that a novel, highly specific small molecule inhibitor of JAB1, CSN5i-3, reduces osteosarcoma cell viability, and has specific effects on the ubiquitin-proteasome system in OS. "

01/01/2022 - "Importantly, CSN5i-3 synergizes with PARP inhibitors to inhibit prostate cancer cell growth. "

08/19/2023 - "In an ex vivo organotypic brain slice model of ischemia/reperfusion stress, MLN4924 protected from neuronal death, while CSN5i-3 impaired neuronal survival. "

08/19/2023 - "Untargeted mass spectrometry-based proteomics revealed that MLN4924 and CSN5i-3 substantially alter the microglial proteome, including inflammation-related proteins. "